Calidi Biotherapeutics, Inc. - CLDI STOCK NEWS

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a definitive agreement for the immediate exercise of certain outstanding Series B and C warrants. This move allows the purchase of up to 10,698,000 shares of Calidi’s common stock at a reduced price of $0.20 per share, generating gross proceeds of approximately $2.1 million.

The funds will be used to support Calidi’s clinical and pre-clinical programs and cover operating expenses. In exchange, Calidi will issue new unregistered warrants with an exercise price of $0.30 per share, exercisable upon shareholder approval, and expiring five and a half years from the issuance date.

This offering is expected to close by June 3, 2024, and is facilitated by Ladenburg Thalmann & Co as the exclusive placement agent. The new warrants will be offered in a private placement under Section 4(a)(2) of the Securities Act of 1933.

ASP Isotopes (Nasdaq:ASPI) and Calidi Biotherapeutics (NYSE American:CLDI) will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing May 25 at 7 p.m. ET. ASP Isotopes CEO Paul Mann will discuss the company's advancements in nuclear medicine and green nuclear energy, emphasizing its strong financial position with no long-term debt and significant cash reserves. H.C. Wainwright reaffirmed its buy rating, raising the price target to $5.50. Calidi Biotherapeutics CEO Allan Camaisa will highlight their cutting-edge oncolytic virotherapy (OV) treatments for cancer, showcasing promising initial study results and innovative IV-based technology for enhanced treatment efficacy.

Calidi Biotherapeutics (NYSE American: CLDI) and Unusual Machines (NYSE American: UMAC) will feature on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing on May 18 at 7 p.m. ET.

Calidi Biotherapeutics, led by CEO Allan Camaisa, specializes in oncolytic virotherapy (OV) for cancer treatment. Their engineered viruses target cancer cells and bolster the immune system, showing promising initial study results. Calidi's unique technologies enhance OV efficacy and treatment potential.

Unusual Machines, headed by CEO Allan Evans, focuses on the drone industry. The company is growing through strategic acquisitions and development of FPV products, aiming to serve various industries like consumer, public safety, and drone delivery. Subsidiaries Fat Shark and Rotor Riot lead in FPV experiences, positioning the company for long-term success.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm, reported its Q1 2024 financial results and business developments. Key highlights include three upcoming posters at the 2024 ASCO Annual Meeting, featuring an update from the ongoing Phase 1 trial of CLD-101 for recurrent high-grade glioma.

Calidi also presented new data on its immunotherapies at the AACR Annual Meeting and unveiled the RTNova systemic delivery platform targeting multiple tumor types. The company completed a $6.1 million public offering, strengthening its balance sheet amid ongoing capital-raising efforts and cost-cutting measures to advance its pipeline.

Financially, Calidi reported a net loss of $7.2 million ($0.20 per share) for Q1 2024, a slight increase from $6.5 million ($0.75 per share) in Q1 2023. R&D expenses increased marginally to $2.7 million, while G&A expenses grew to $4.0 million from $2.8 million. The company ended Q1 2024 with $1.2 million in cash and $0.2 million in restricted cash.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced the acceptance of three abstracts for presentation at the 2024 ASCO Annual Meeting. The abstracts focus on their innovative programs for the treatment of high-grade glioma and solid tumors. Calidi will present updates on their CLD-101, RTNova, and CLD-201 programs, showcasing their cutting-edge therapeutic candidates.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is hosting an exclusive investor webinar on April 24, 2024, featuring key executives discussing the company's technology platforms and development pipeline. Investors can register for the free event and participate in a live Q&A session.

Calidi Biotherapeutics, Inc. (CLDI) has successfully closed a public offering, raising $6.1 million through the issuance of common stock and warrants. The offering included 15,197,500 shares at an effective price of $0.40 per share. The company plans to utilize the proceeds for working capital, general corporate purposes, pre-clinical and clinical trials, and debt repayment. Ladenburg Thalmann & Co. Inc. served as the placement agent for the offering.

Calidi Biotherapeutics, Inc. (CLDI) announces the pricing of a $6.1 million public offering, consisting of common stock and warrants, to fund its immunotherapy development. The offering includes 15,197,500 shares at $0.40 per share, with various warrant types. The gross proceeds are approximately $6.1 million before expenses.

Calidi Biotherapeutics presents new data at AACR Annual Meeting 2024 showcasing the immunomodulatory role of stem cells in antitumor virotherapies. The company's platforms CLD-101 and CLD-201 aim to enhance antitumor activity through innovative stem cell technology.